Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023
2023年9月13日 - 5:30AM
ビジネスワイヤ(英語)
Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR), a
structural heart company developing the world’s only
balloon-expandable, single-piece transcatheter aortic valve (TAVR)
for the treatment of aortic stenosis announced today that Wayne
Paterson, the Chief Executive Officer of Anteris will present at
the Cantor Fitzgerald Annual Global Healthcare Conference in New
York, NY on Tuesday, September 26, 2023, at 2:45 p.m. Eastern
Time.
Mr. Paterson will present the latest clinical data for DurAVR™,
the Company’s lead technology and a best-in-class TAVR for the
treatment of aortic stenosis. This will be followed with a fireside
chat with Cantor’s medtech analyst, Ross Osborn. Investor
one-on-one meetings are also available at the conference, and
institutional investors interested in scheduling a meeting should
contact their Cantor sales person or Cantor’s Corporate Access team
at corporateaccess@cantor.com
DurAVR™ THV continues to be investigated in a clinical trial
setting for severe aortic stenosis patients in two Early
Feasibility Studies (EFS) being conducted in the U.S.
(ClinicalTrials.gov NCT05712161) and Europe (Clinicaltrials.gov
NCT05182307). One-year data from European EFS of DurAVR™ was
presented at the TVT Structural Heart Conference on June 9th 2023
and available on the investor portal of the Company’s website.
Thirty (30) day data results from the ongoing U.S. EFS of DurAVR™
is targeted for 4Q2023.
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart
company committed to designing, developing, and commercialising
innovative medical devices. Founded in Australia, with a
significant presence in Minneapolis, USA, a MedTech hub, Anteris is
science-driven, with an experienced team of multidisciplinary
professionals delivering transformative solutions to structural
heart disease patients.
The Company’s lead product, DurAVR™, is a transcatheter heart
valve (THV) for the treatment of aortic stenosis. DurAVR™ THV has
been designed in partnership with the world’s leading
interventional cardiologists and cardiac surgeons and is the first
transcatheter aortic valve replacement (TAVR) to use a single piece
of bioengineered tissue. This biomimetic valve is uniquely shaped
to mimic the performance of a healthy human aortic valve.
The ComASUR™ Delivery System is designed to provide controlled
deployment and accurate placement of the DurAVR™ THV with
balloon-expandable delivery, allowing precise alignment with the
heart’s native commissures to achieve desired valve
positioning.
Anteris Technologies is set to revolutionise the structural
heart market by delivering clinically superior solutions that meet
significant unmet clinical needs.
Authorisation and Additional Information:
This announcement was authorized by the Board of Directors.
Website www.anteristech.com Twitter @AnterisTech Facebook
www.facebook.com/AnterisTech LinkedIn
https://www.linkedin.com/company/anteristech
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912585997/en/
Investor Relations (U.S.) Malini Chatterjee, Ph.D.
Managing Director Blueprint Life Science Group +1 917 330 4269
Avaron Mining (TSXV:AVR)
過去 株価チャート
から 11 2024 まで 12 2024
Avaron Mining (TSXV:AVR)
過去 株価チャート
から 12 2023 まで 12 2024